MARKET

TTNP

TTNP

Titan Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.800
-0.080
-2.78%
After Hours: 2.840 +0.04 +1.43% 19:19 03/05 EST
OPEN
2.990
PREV CLOSE
2.880
HIGH
2.990
LOW
2.560
VOLUME
1.04M
TURNOVER
--
52 WEEK HIGH
14.06
52 WEEK LOW
2.560
MARKET CAP
27.62M
P/E (TTM)
-0.3787
1D
5D
1M
3M
1Y
5Y
Opioid Use Disorder Market Size, Share, Growth, Industry Analysis, Opportunities and Forecast 2019-2025
Mar 01, 2021 (Market Insight Reports) -- The global opioid use disorder market is estimated to witness significant growth during the forecast period...
Market Insight Reports · 6d ago
Top Penny Stocks To Buy Right Now? 4 To Watch After A Pullback
Feb 25, 2021 (Penny Stocks via COMTEX) -- 4 Biotech Penny Stocks To Watch Heading Into March 2021 Like any good investor, the key to picking penny stocks to...
Penny Stocks · 02/25 18:43
Penny Stocks To Buy With Analysts Targeting 76%-209% Upside
Feb 24, 2021 (Penny Stocks via COMTEX) -- Analysts Are Bullish On These 4 Penny Stocks We've discussed penny stocks and analyst ratings many times before....
Penny Stocks · 02/24 21:12
Best Penny Stock To Buy Next Week? 5 Biotechs You Might've Missed
Feb 24, 2021 (Penny Stocks via COMTEX) -- 5 Biotech Penny Stocks to Watch in February 2021 With February in full swing, investors are still searching for the...
Penny Stocks · 02/24 21:11
UK Opioid Use Disorder (Oud) Market Share, Size Industry Development Analysis, Global Trends , Growth Factors, CAGR Status, Industry Insights by Top Key Players and Forecast Period (2021-2027)
Feb 22, 2021 (Heraldkeepers) -- Pre & Post Covid-19 Impact and Recovery Analysis (Estimates) is Covered in Opioid Use Disorder (Oud) Market Research...
Heraldkeepers · 02/22 10:55
Immunome, Avinger leads healthcare gainers; MEDNAX, ReWalk Robotics among major losers
Gainers: Immunome (IMNM) +93%, Avinger (AVGR) +33%, Titan Pharmaceuticals (TTNP) +17%, GBS (GBS) +15%, VistaGen Therapeutics (VTGN) +15%.Losers: MEDNAX (MD) -23%, ReWalk Robotics (RWLK) -21%, Shineco (TYHT) -19%, Check-Cap (CHEK) -15%, Advaxis (ADXS) -12%.
Seekingalpha · 02/18 16:01
TWLO, RIGL, ONTX and MACK among premarket gainers
Greenland Technologies Holding Corporation (GTEC) +186% on signing co-operation agreement with SOCMA.Immunome (IMNM) +152% on discovery of antibodies neutralizing SARS-CoV-2 variants.Avinger (AVGR) +57%.Heritage Global (HGBL) +42%.U.S. Well Services (USWS)...
Seekingalpha · 02/18 13:26
DJ Titan Pharmaceuticals Price Target Announced at $11.00/Share by Maxim Group
Dow Jones · 02/18 12:42
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TTNP. Analyze the recent business situations of Titan Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TTNP stock price target is 0.8000 with a high estimate of 0.8000 and a low estimate of 0.8000.
EPS
Institutional Holdings
Institutions: 46
Institutional Holdings: 215.63K
% Owned: 2.19%
Shares Outstanding: 9.86M
TypeInstitutionsShares
Increased
9
66.00K
New
10
-155.49K
Decreased
2
32
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.51%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Chief Executive Officer/Executive Director
Marc Rubin
President/Chief Operating Officer/Chief Scientific Officer/Director
Katherine DeVarney
Independent Director
Joseph Akers
Independent Director
M. David MacFarlane
Lead Director
Seghi Recli
Independent Director
James McNab
Independent Director
Scott Smith
No Data
About TTNP
Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company's segment is engaged in the development of pharmaceutical products. The Company's product development programs utilize its long-term drug delivery platform, ProNeura. The Company's drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan's ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson's disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism.

Webull offers kinds of Titan Pharmaceuticals, Inc. stock information, including NASDAQ:TTNP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TTNP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TTNP stock methods without spending real money on the virtual paper trading platform.